SAILIFE Sai Life Q4 FY25 results (Jan–Mar 2025) and concall
Sai Life Sciences delivered a strong FY25 performance characterized by significant margin expansion and a doubling of net profit. The company is successfully transitioning its revenue mix toward higher-margin CRO services and deepening relationships with top global pharma clients. Management is signaling aggressive growth for the future with a massive ₹700 crore capex plan for FY26 to capture supply chain shifts away from China.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 396 | 440 | 580 |
| EBITDA | 102 | 120 | 158 |
| Net profit | 42 | 54 | 88 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
